ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Orbital Therapeutics has launched with the goal of developing RNA therapies for a broad range of human diseases. The Massachusetts-based biotech firm also aims to improve the stability of RNA therapeutics and widen the cell and tissue types they can target. As part of the launch, Orbital has entered a license and research collaboration with the gene-editing company Beam Therapeutics. The firms will grant each other access to their RNA and nonviral delivery technologies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter